Light AI Bets on AI Diagnostics in New Zealand Amid Financial Headwinds

VANCOUVER, BC – June 15, 2026 – In a move that epitomizes the high-risk, high-reward nature of the modern health-tech economy, Light AI Inc. has launched a company-funded field study in New Zealand for its QuickScan™ Strep A platform. The initiative, announced today, aims to turn everyday smartphones into powerful diagnostic tools, a classic example of the operational innovation that can redefine an industry. However, this pivotal clinical step is set against a backdrop of financial pressures and the formidable challenge of securing regulatory approval, making this New Zealand gambit a critical test of both the technology's promise and the company's resilience.

The Strategic Bet on Accessible Diagnostics

At its core, Light AI's strategy is to decouple diagnostics from specialized hardware and centralized labs. The QuickScan™ platform uses a proprietary AI algorithm to analyze a smartphone image of a patient's throat, delivering a result in seconds. This app-based solution eliminates the need for uncomfortable throat swabs, lab processing, and proprietary reading devices, democratizing access by leveraging the 4.5 billion smartphones already in circulation globally. This operational shift—moving the point of diagnosis directly into community and school-based settings—is the disruptive force the company is banking on.

"New Zealand provides an important opportunity to evaluate how AI-enabled health-tech tools may support improved access to screening and care in community settings," said John R. Luna, Chief Executive Officer of Light AI. He emphasized that the study is designed to generate insights that "may support future commercial deployment opportunities in New Zealand and potentially other international markets."

The technology's potential is underscored by impressive pre-FDA validation data, where the algorithm demonstrated 96.57% accuracy in differentiating between viral and bacterial pharyngitis. Critically, it achieved a 100% Negative Predictive Value (NPV), meaning it was perfectly reliable in confirming the absence of Group A Streptococcus (GAS). For clinicians, a high NPV is invaluable for confidently ruling out bacterial infections and avoiding the prescription of unnecessary antibiotics, a key goal in the fight against antimicrobial resistance.

A Public Health Mission with a Business Motive

The choice of New Zealand for this crucial field study is no accident. The country faces a significant public health challenge with Strep A and its severe complication, Rheumatic Heart Disease (RHD), which disproportionately affects Māori and Pacific peoples. This makes the collaboration with the National Hauora Coalition (NHC), a Māori-led health organization, a strategically astute move. The NHC provides deep-rooted community access and an operational framework to test QuickScan™'s real-world effectiveness, integration into existing workflows, and user acceptance.

"We look forward to evaluating the implementation and effectiveness of Light AI's QuickScan™ platform," said Dr. Rachel Brown, Chief Executive of the NHC, noting the study will help assess its potential in community-based screening programs. This partnership provides Light AI with an ideal proving ground to demonstrate its value proposition not just technologically, but as a tool for health equity.

By tackling a disease that affects over 600 million people annually and, if untreated, contributes to a global economic burden from RHD exceeding $1 trillion, Light AI is positioning its solution as a massive cost-saver for global healthcare systems. A successful outcome in New Zealand would provide a powerful case study for deployment in other nations struggling with similar health disparities and economic pressures.

The High-Stakes Path to Commercialization

While the technology is promising, Light AI's journey is fraught with the financial realities of a pre-revenue development-stage company. The company's own auditor issued a "going concern" doubt in its recent annual report, highlighting its dependence on securing additional capital to fund its ambitious plans. Operating expenses have climbed significantly, reaching $4.2 million in the first quarter of 2025 as the company ramped up R&D, marketing, and an FDA pivotal clinical trial in the United States.

Investor intelligence paints a picture of a company in a crucial transitional phase. With cash reserves at $11.9 million as of March 31, 2025, the firm is actively managing its runway. It recently announced a C$5 million secured convertible debenture financing, a vital injection of capital expected to close this month. This financial maneuvering is typical for a company at this stage, but it underscores the immense pressure to deliver positive results. The company's stock (CBOE CA: ALGO), which has seen significant volatility over the past year, reflects this uncertainty, with its market capitalization hovering around C$38 million.

The New Zealand field study, therefore, is more than a clinical evaluation; it is a catalyst for the company's financial future. Positive data on implementation and workflow integration will be critical for de-risking the technology in the eyes of regulators, future commercial partners, and, most importantly, investors.

Navigating the Regulatory Gauntlet and Competitive Field

Beyond financing, Light AI's greatest hurdles lie in the complex and demanding regulatory landscapes of its target markets. The data gathered in New Zealand will be instrumental in supporting applications to Medsafe (New Zealand), as well as providing supplementary real-world evidence for its ongoing FDA process in the U.S. and future submissions in Canada and Europe. Proving that the QuickScan™ platform is not only accurate but also safe and effective in diverse, non-clinical settings is paramount.

In the competitive arena, QuickScan™'s primary advantage over existing swab-based rapid antigen tests is its non-invasive nature and integration with ubiquitous hardware. This could prove to be a decisive factor in school-based screening programs and for patients who are hesitant about invasive tests. This unique selling proposition, combined with the company's broader vision of creating a "Digital Clinical Lab" for a multitude of conditions, forms the foundation of its long-term growth strategy. The leadership of founder Peter Whitehead, who previously invented and successfully commercialized the VELscope oral cancer screening device, lends valuable credibility to this ambitious vision.